Quick Answer
Spyre Therapeutics, Inc. reported Earnings Per Share Diluted of $49.12 (loss) per share for the year ending 2023.
- Spyre Therapeutics, Inc. showed a decrease of -97.6% in Earnings Per Share Diluted from 2022 to 2023.
- This data is from Spyre Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 29, 2024.
- XBRL data for this metric is available from 2020 to 2023 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2021: $0.10 (loss) per share | Q3 2021: $0.31 (loss) per share | Q1 2022: $0.37 (loss) per share | Q2 2022: $0.27 (loss) per share | Q3 2022: $4.84 (loss) per share | Q1 2023: $4.89 (loss) per share | Q2 2023: $56.79 (loss) per share | Q3 2023: $9.34 (loss) per share | Q1 2024: $1.20 (loss) per share | Q2 2024: $0.86 (loss) per share | Q3 2024: $1.36 (loss) per share.
- Over the full 4 years of available data (2020 to 2023), Spyre Therapeutics, Inc.'s Earnings Per Share Diluted has declined by 3,131.6%.
- Historical annual values: Fiscal year 2023: $49.12 (loss) per share | Fiscal year 2022: $24.86 (loss) per share | Fiscal year 2021: $25.02 (loss) per share | Fiscal year 2020: $1.52 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: